Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOIQ4K)

Drug Name

Auryntricarboxylic acid (ATA) Drug Info

Synonyms

244218-51-7; UNII-7I21WLZ2FP; TCMDC-125882; JTC-801 HCl; 7I21WLZ2FP; N-(4-amino-2-methylquinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamide hydrochloride; N-(4-Amino-2-methyl-6-quinolinyl)-2-[(4-ethylphenoxy)methyl]benzamide hydrochloride; C26H26ClN3O2; N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide hydrochloride; N-(4-amino-2-methylquinolin-6-yl)-2-[(4-ethylphenoxy)methyl]benzamide hydrochloride; AC1NSKGE; MLS006011235; SCHEMBL2240337; CHEMBL531742; CTK8E7568; DTXSID10415525

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

TTD Drug ID: DMOIQ4K

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting von Willebrand factor (VWF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vonvendi	DMI783H	Von willebrand disease	3B12	Approved	[2]
Caplacizumab	DMPUKA7	Thrombotic thrombocytopenic purpura	3B64.14	Approved	[3]
Recombinant von Willebrand factor/recombinant Factor VIII complex	DM7JFDO	Von willebrand disease	3B12	Phase 3	[4]
ALX-0081	DM7EBH9	Thrombotic thrombocytopenic purpura	3B64.14	Phase 3	[5]
ARC1779	DM7PCLY	Intracranial embolism	8B22.1	Phase 2	[6]
BT-200	DM1EYOF	Von willebrand disease	3B12	Phase 2	[7]
DA-697b	DMBRN2G	Thrombosis	DB61-GB90	Phase 1	[8]
DTRI-031	DM0BCT7	Ischemic stroke	8B11.5Z	Phase 1	[9]
Mitoflaxone	DMO06JV	Solid tumour/cancer	2A00-2F9Z	Terminated	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
von Willebrand factor (VWF)	TT3SZBT	VWF_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
2	Clinical pipeline report, company report or official report of Vonvendi.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4	6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418.
5	Clinical pipeline report, company report or official report of Ablynx
6	Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2028-2037.
7	Clinical pipeline report, company report or official report of Guardian Theapeutics
8	A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010 Jan;103(1):205-12.
9	Clinical pipeline report, company report or official report of Basking Biosciences